Search

Your search keyword '"Shioyama Y"' showing total 80 results
Start Over Author "Shioyama Y" Publisher elsevier b.v.
80 results on '"Shioyama Y"'

6. Prognosis after Local Recurrence or Metastases in Medically Operable Stage I Non-Small Cell Lung Cancer Patients Treated By Stereotactic Body Radiotherapy.

Author

Onishi, H., Shioyama, Y., Matsuo, Y., Takayama, K., Miyakawa, A., Yamashita, H., Nomiya, T., Matsumo, Y., Matsushita, H., Kimura, T., Murakami, N., Ishiyama, H., Uno, T., Takanaka, T., Katoh, N., Takeda, A., Nakata, K., Ogawa, K., Nihei, K., and Aoki, M.

Subjects
*NON-small-cell lung carcinoma, *STEREOTACTIC radiotherapy, *METASTASIS
Published
2019
Full Text
View/download PDF

10. Multi-institutional Retrospective Study of Carbon Ion Radiation Therapy for Stage I Non-Small Cell Lung Cancer: Japan Carbon Ion Radiation Oncology Study Group.

Author

Shioyama, Y., Yamamoto, N., Saitoh, J.I., Fujii, O., Matsunobu, A., Ohno, T., Okimoto, T., Tsuji, H., Kamada, T., Nakano, T., and Nemoto, K.

Subjects
*CARBON, *CANCER treatment, *NON-small-cell lung carcinoma, *CANCER radiotherapy, *RADIATION doses, *RETROSPECTIVE studies, *THERAPEUTICS
Published
2016
Full Text
View/download PDF

11. Excellent Survival! Multi-Institutional Study of Stereotactic Body Radiation Therapy for Medically Operable and Young (70 Years Old or Younger) Patients With Stage I Non-Small Cell Lung Cancer.

Author

Onishi, H., Shioyama, Y., Matsumoto, Y., Takayama, K., Matsuo, Y., Miyakawa, A., Yamashita, H., Matsushita, H., Aoki, M., Nihei, K., Kimura, T., Ishiyama, H., Murakami, N., Nakata, K., Takeda, A., Uno, T., Nomiya, T., Takanaka, T., and Seo, Y.

Subjects
*CANCER treatment, *NON-small-cell lung carcinoma, *STEREOTACTIC radiotherapy, *ONCOLOGIC surgery, *TUMOR classification, *ONCOLOGY, *MEDICAL research
Published
2016
Full Text
View/download PDF

12. Multi-institutional Retrospective Study of Stereotactic Body Radiation Therapy for Stage I Small Cell Lung Cancer: Japan Radiation Oncology Study Group (JROSG).

Author

Shioyama, Y., Nagata, Y., Komiyama, T., Takayama, K., Shibamoto, Y., Ueki, N., Yamada, K., Kozuka, T., Kimura, T., and Matsuo, Y.

Subjects
*STEREOTACTIC radiotherapy, *CANCER treatment, *SMALL cell lung cancer, *MAGNETIC resonance imaging of the brain, *HEALTH outcome assessment, *CANCER chemotherapy
Published
2015
Full Text
View/download PDF

13. Japanese Multi-institutional Study of Stereotactic Body Radiation Therapy for 661 Medically Operable Patients With Stage I Non-Small Cell Lung Cancer.

Author

Onishi, H., Shioyama, Y., Matsumoto, Y., Takayama, K., Matsuo, Y., Miyakawa, A., Yamashita, H., Matsushita, H., Aoki, M., Nihei, K., Kimura, T., and Ishiyama, H.

Subjects
*STEREOTACTIC radiotherapy, *NON-small-cell lung carcinoma, *CANCER treatment, *HEALTH outcome assessment, *ONCOLOGIC surgery, *FOLLOW-up studies (Medicine), *PATIENTS
Published
2015
Full Text
View/download PDF

17. Stereotactic Body Radiation Therapy for Stage I Small Cell Lung Cancer: Clinical Outcomes in a Japanese Multi-institutional Retrospective Study.

Author

Shioyama, Y., Onishi, H., Takayama, K., Matsuo, Y., Takeda, A., Yamashita, H., Miyakawa, A., Murakami, N., Aoki, M., and Matsushita, H.

Subjects
*CANCER treatment, *SMALL cell lung cancer, *STEREOTACTIC radiotherapy, *CANCER radiotherapy, *CLINICAL trials, *HEALTH outcome assessment, *RETROSPECTIVE studies
Published
2013
Full Text
View/download PDF

37. Carbon-Ion Radiotherapy for Postoperative Locoregional Recurrence of Pancreatic Cancer.

Author

Terashima, K., Suefuji, H., Matsunobu, A., Toyama, S., Fukunishi, K., Ohta, W., and Shioyama, Y.

Subjects
*CANCER relapse, *PANCREATIC cancer, *PROGRESSION-free survival, *STOMACH ulcers, *PANCREATIC surgery, *RADIOTHERAPY safety, *RADIOTHERAPY
Abstract

To evaluate the efficacy and safety of carbon-ion radiotherapy (CIRT) for patients with locoregional recurrence after surgery for pancreatic cancer. A total of 32 patients, who underwent CIRT for locoregional recurrence after surgery for pancreatic cancer between January 2015 and July 2022, were retrospectively analyzed. The total dose of CIRT was 55.2 Gy (RBE) in 12 fractions. Concurrent chemotherapy included gemcitabine for 17 patients and S-1 for 3 patients. The overall survival (OS), local control (LC), progression free survival (PFS), and toxicity were evaluated. The median follow-up time from the initiation of CIRT was 21.4 months. The 1- and 2-year OS were 84.2 and 55.3%, respectively. The median survival were 24.2 months. The 1- and 2-year PFS were 40.7 and 14.8%, respectively, with a median PFS of 9.9 months. The 1- and 2-year LC were 100 and 50.2 %, respectively. 4 patients experienced grade 3 acute toxicities: hematologic toxicity in 2 patients, anorexia in 1 patient and gastric ulcer/bleeding in 1 patient. The patients with grade 3 gastric ulcer/bleeding underwent blood transfusion and recovered quickly. There was no grade 4 or 5 acute toxicity. In terms of late toxicity, no grade 3 or greater toxicity was observed. CIRT for postoperative locoregional recurrence of pancreatic cancer resulted in relatively long survival with acceptable toxicity. CIRT may be one of the choices of treatment for patients with this disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

38. Proton and Carbon Ion Radiotherapy for Operable Early-Stage Lung Cancer: 3-Year Results of a Prospective Nationwide Registry.

Author

Harada, H., Suefuji, H., Mori, K., Ishikawa, H., Nakamura, M., Tokumaru, S., Murakami, M., Ogino, T., Iwata, H., Tatebe, H., Kubo, N., Waki, T., Yoshida, D., Aoyama, H., Araya, M., Nakajima, M., Nakayama, H., Satouchi, M., and Shioyama, Y.

Subjects
*LUNG cancer, *RADIOTHERAPY, *PROGRESSION-free survival, *PROTONS, *OVERALL survival, *CARBON
Abstract

The purpose of this analysis was to report subset analysis as to progression-free survival (PFS) and overall survival (OS) of particle-beam radiation therapy for operable early-stage lung cancer. Patients of early-stage lung cancer (T1-T2aN0) who were eligible for radical surgery but did not wish to undergo surgery were treated by proton-ion (PT) or carbon-ion (CT) radiation therapy and enrolled in Japanese prospective registry. In this analysis, PFS and OS by clinical stage, tumor location, pathological confirmation and particle-ion type were evaluated. A total of 274 patients were enrolled and included in efficacy and safety analyses. Most tumors were adenocarcinoma (44%), and 105 (38%) were not histologically confirmed and diagnosed clinically. 250 (91%) of 274 patients had tumors that were peripherally situated. 138 (50%) and 136 (50%) patients were treated by PT and CT, respectively. The median follow-up time for all censored patients was 42.8 months (IQR 36.7 – 49.0). No grade 3 or severe treatment-related toxicity was observed. 3-year PFS was 81% (95% CI;76–86) and OS was 93% (95% CI;89–96), respectively. As to particle-ion type, 3-year PFS were 79.0% and 81.9% in PT and CT (p = 0.19), and 3-year OS were 93.9% and 91.1% in PT and CT (P = 0.72), respectively. For PFS, pathological confirmation, clinical stage was significant factors but there were no significant differences by tumor location or particle-ion type; for OS, clinical stage was significant factor but there was no significant difference on pathological confirmation, tumor location or particle-ion type (Table1). Table 1. 3-year PFS and OS Particle therapy for operable early-stage lung cancer resulted in excellent 3-year OS and PFS on each subset. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Comparison of Treatment Planning for Carbon Ion Radiation Therapy, Proton Therapy and Intensity Modulated Radiation Therapy for Spinal Tumors Encircling the Spinal Cord.

Author

Matsumoto, K., Nakamura, K., Shioyama, Y., Sasaki, T., Ohga, S., Yamaguchi, T., Yoshitake, T., Asai, K., Ohshima, K., Inamori, M., Hiramine, K., and Honda, H.

Subjects
*RADIOTHERAPY treatment planning, *PROTON therapy, *INTENSITY modulated radiotherapy, *SPINAL cord cancer, *CANCER radiotherapy
Published
2015
Full Text
View/download PDF

40. Stereotactic Body Radiation Therapy for Histologically Confirmed Stage I Non-Small Cell Lung Cancer: Treatment Results and Patterns of Recurrence.

Author

Asai, K., Nakamura, K., Shioyama, Y., Sasaki, T., Ohga, S., Yamaguchi, T., Yoshitake, T., Baba, S., Kawanami, S., Ohshima, K., Matsumoto, K., Inamori, M., Hiramine, K., and Honda, H.

Subjects
*SMALL cell lung cancer, *CANCER treatment, *STEREOTACTIC radiotherapy, *CANCER relapse, *MEDICAL physics, *CLINICAL trials, *CANCER radiotherapy
Published
2015
Full Text
View/download PDF

42. Treatment Outcome of Primary Ocular Adnexal MALT Lymphoma by Radiation Therapy: Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System for Ocular Adnexal MALT Lymphoma.

Author

Ohga, S., Nakamura, K., Shioyama, Y., Sasaki, T., Yoshitake, T., Terashima, K., Kaori, A., Matsumoto, K., and Honda, H.

Subjects
*MUCOSA-associated lymphoid tissue lymphoma, *ADNEXAL diseases, *CANCER radiotherapy, *METASTASIS, *ADNEXA oculi, *THERAPEUTICS
Published
2014
Full Text
View/download PDF

50. Phase I/II clinical study of percutaneous vertebroplasty (PVP) as palliation for painful malignant vertebral compression fractures (PMVCF): JIVROSG-0202.

Author

Kobayashi, T., Arai, Y., Takeuchi, Y., Nakajima, Y., Shioyama, Y., Sone, M., Tanigawa, N., Matsui, O., Kadoya, M., and Inaba, Y.

Subjects
*INTERVENTIONAL radiology, *ANALGESIA, *QUALITY of life, *PALLIATIVE treatment, *PHARMACOLOGY
Abstract

Background: The safety and efficacy of percutaneous vertebroplasty (PVP), a new treatment modality for painful malignant vertebral compression fractures (PMVCF) using interventional radiology techniques, were evaluated prospectively. [ABSTRACT FROM PUBLISHER]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results